简要标题 Sacituzumab Govitecan in Primary HER2-negative Breast Cancer 临床分期 Phase 3 招募状态 Active, not recruiting 首次公开日期 2020-10-20 条件/疾病 Triple Negative Breast Cancer | HER2-negative Breast Cancer 干预/治疗 Sacituzumab govitecan | Capecitabine | Carboplatin | Cisplatin 申办方 Germa...
inoperable or metastatic HR-positive, HER2-negative breast cancer, progressed on or are not eligible for endocrine therapy, have an ECOG performance status of 0 or 1, at least 1 measurable lesion, adequate organ and bone marrow function, and a minimum life expectancy of 12 wee...
HER2-negative metastatic breast cancer, as part of the phase 1/2 AMEERA-1 trial (NCT03284957).4The trial enrolled postmenopausal patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer with measurable disease and who received...
In this first-line MBC phase II trial, the combination of docetaxel with bevacizumab resulted in a confirmed ORR of 51% for patients with HER2-negative, measurable disease. This is similar to the 49% response rate reported for the combination of paclitaxel and bevacizumab in patients with measur...
measurable lesion based on RECIST 1.1, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, a life expectancy of at least 12 weeks, and adequate organ function. Prior trastuzumab was allowed. Women with childbearing potential must have a negative pregnancy test at screening...
biliary tract cancer, colorectal cancer, non-small-cell lung cancer, uterine cancer and bladder cancer1. HER2 is a prognostic biomarker of breast cancer, with HER2 overexpression/amplification associated with poorer outcomes and higher rates of disease relapse and mortality versus HER2-negative cases2...
Our study also verified the conclusion reported in the above studies that ER and PR-negative patients were more likely to achieve tpCR than positive patients. The possible reasons are that HR-positive patients are not sensitive to chemotherapy, or HR-negative breast cancer is characterized by ...
breast cancer will eventually develop brain metastases during their respective course of disease, making metastatic breast cancer the second most common cause of brain metastases among all solid tumors after lung cancer1, with the highest incidences reported in triple-negative and HER2-positive disease...
The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor-positive, HER2-negative breast cancer were treated with datopotamab deruxtecan.
Open Access Journal of Clinical Trials Dovepress open access to scientific and medical research Open Access Full Text Article STUDY PROTO CO L Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe ...